Showing results (471-480 of 601) with videos related to

Sort By:
Pageof 61
Journal of Neuroimmunology|July 23, 2015
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-upTobias Derfuss, François Curtin, Claudia Guebelin, et al.
Journal of Neurology|August 5, 2015
Predictors of disease activity in 857 patients with MS treated with interferon beta-1bHans-Peter Hartung, Ludwig Kappos, Douglas S Goodin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2018
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II studyJeffrey A Cohen, Giancarlo Comi, Douglas L Arnold, et al.
Neurology|July 12, 2020
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosisGavin Giovannoni, Volker Knappertz, Joshua R Steinerman, et al.
The Lancet. Neurology|July 9, 2010
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosisChris H Polman, Antonio Bertolotto, Florian Deisenhammer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 24, 2022
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendationsWallace J Brownlee, Christian Wolf, Hans-Peter Hartung, et al.
Multiple Sclerosis and Related Disorders|April 23, 2021
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development programKrzysztof W Selmaj, Jeffrey A Cohen, Giancarlo Comi, et al.
Annals of Clinical and Translational Neurology|December 1, 2020
Long-term adherence and response to botulinum toxin in different indicationsJohn-Ih Lee, Alexander Jansen, Sara Samadzadeh, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 6, 2018
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension studySibyl Wray, Eva Havrdova, David R Snydman, et al.
Annals of Clinical and Translational Neurology|July 10, 2025
Digital Activity Markers in Chronic Inflammatory Demyelinating PolyneuropathyLars Masanneck, Jan Voth, Noëmi Gmahl, et al.
Pageof 61